First results from the RETgistry: A global consortium for the study of resistance to RET inhibition in <i>RET</i>-altered solid tumors.
Alissa J. Cooper(Massachusetts General Hospital), Julia Rotow(University of California, San Francisco), Lori J. Wirth(Massachusetts General Hospital), Herbert H. Loong(Memorial Sloan Kettering Cancer Center), Jyoti D. Patel(Memorial Sloan Kettering Cancer Center), Natalie F. Uy(University of Washington), Stephen V. Liu(Georgetown University), Martin Früh(University of Bern), Benjamin Solomon(Peter MacCallum Cancer Centre), Katherine E. Smith(Mayo Clinic in Arizona), Misako Nagasaka(University of California, Irvine), Alexander Drilon(Memorial Sloan Kettering Cancer Center), Oliver Gautschi(Université Toulouse III - Paul Sabatier), Georg Pall(University Hospital Innsbruck), Justin F. Gainor(Harvard University), Jonathan W. Riess(University of California Davis Medical Center), Dae Ho Lee(Asan Medical Center), Nathan A. Pennell(Cleveland Clinic), Beow Y. Yeap(Harvard University)
Cited by 8
Related Papers
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2010|4.5k
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.5k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k
First-Line Crizotinib versus Chemotherapy in <i>ALK</i>-Positive Lung Cancer
|New England Journal of Medicine|2014|3.2k
Crizotinib in <i>ROS1</i>-Rearranged Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2014|2k